ClinicalTrials.gg
CompletedNCT03029949Updated Nov 15, 2023

Acceptance and Commitment Therapy With Vestibular Rehabilitation for Chronic Dizziness

An interventional study of ACT with VR and self-treatment VR in Chronic Dizziness, sponsored by Nagoya City University. Completed at 1 site in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by Nagoya City University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Study summary

The purpose of this study is to examine the effectiveness of group acceptance and commitment therapy with vestibular rehabilitation for chronic dizziness, in comparison with self-treatment vestibular rehabilitation in addition to clinical management.

Read the detailed description

The purpose of this study is to examine whether group acceptance and commitment therapy combined with vestibular rehabilitation in addition to clinical management for patients with persistent postural-perceptual dizziness is more effective than treatment-as-usual(TAU), which is self-treatment vestibular rehabilitation in addition to clinical management.

02

Conditions studied

  • Chronic Dizziness

Browse trials for

Keywords

  • chronic dizziness
  • persistent postural-perceptual dizziness
  • acceptance and commitment therapy
  • behavior therapy
  • vestibular rehabilitation
03

In context

Dizziness

228 studies on the registry are indexed under Dizziness; 57 are open to participants now.

This study's enrollment of 66 is above the median of 42 across 172 interventional studies indexed under Dizziness.

Browse Dizziness studies →

Lead sponsor

Nagoya City University is the lead sponsor of 14 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persistent postural-perceptual dizziness (diagnosed by the diagnostic guideline of ICD-11 beta version at Dec. 2016)
  • Existing handicap due to dizziness (DHI equal to or more than 16)
  • Written consent

Exclusion criteria

Exclusion Criteria:

  • Vertigo/dizziness/unsteadiness by organic brain diseases, diagnosed by neuro-otologist
  • Vertigo/dizziness/unsteadiness explained by only organic cause or drug, diagnosed by neuro-otologist
  • Physical status inappropriate for psychotherapy or vestibular rehabilitation
  • Current psychiatric disorder other than anxiety disorders, somatic symptom disorder, or illness anxiety disorder (), diagnosed by psychiatrist
  • History of schizophrenia or bipolar disorder diagnosed by psychiatrist
  • Increased risk of suicide or self-harm diagnosed by psychiatrist
  • Started or increased SSRI/Venlafaxine within 1 month before treatment
  • Any cognitive behavioral therapy or vestibular rehabilitation except this study
  • Otological surgery or device therapy for dizziness
  • Insufficient understanding of the Japanese language
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    ACT with VR

    acceptance and commitment therapy with vestibular rehabilitation in addition to clinical management

    Behavioral: ACT with VR · Other: clinical management

  • Active comparator
    Self-treatment VR

    self-treatment vestibular rehabilitation in addition to clinical management

    Behavioral: self-treatment VR · Other: clinical management

Interventions

  • BehavioralACT with VR

    6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment

  • Behavioralself-treatment VR

    booklet written on vestibular rehabilitation for self-treatment

  • Otherclinical management

    clinical management and pharmacotherapy as usual for chronic dizziness

06

What researchers measure

Primary outcomes

  1. Handicap due to dizziness

    The total score of Dizziness Handicap Inventory (DHI) (The DHI scores range from 0 to 100 points. The higher the score, the greater the handicap.)

    Time frame: Post-treatment and 1, 3, and 6 months after treatment (The time point of primary interest is 3 months after treatment.)

Secondary outcomes

  1. Response

    Decrease in the total score of DHI equal to or more than 11

    Time frame: Post-treatment and 1, 3, and 6 months after treatment

  2. Remission

    The total score of DHI equal to or less than 14

    Time frame: Post-treatment and 1, 3, and 6 months after treatment

  3. Frequency of dizziness-related symptoms

    The total score of Vertigo Symptom Scale-short form (VSS-sf) (The VSS-sf scores range from 0 to 60 points. The higher the score, the worse.)

    Time frame: Post-treatment and 1, 3, and 6 months after treatment

  4. Anxiety

    The anxiety subscale score of Hospital Anxiety and Depression Scale (HADS) (The HADS-anxiety scores range from 0 to 21 points. The higher the score, the worse.)

    Time frame: Post-treatment and 1, 3, and 6 months after treatment

  5. Depression

    The depression subscale score of HADS (The HADS-depression scores range from 0 to 21 points. The higher the score, the worse.)

    Time frame: Post-treatment and 1, 3, and 6 months after treatment

  6. Recovery process

    The total score of Recovery Assessment Scale (RAS) (The RAS scores range from 24 to 120 points. The higher the score, the better.)

    Time frame: Post-treatment and 1, 3, and 6 months after treatment

  7. Health-related quality of life

    The score of EuroQOL 5 dimensions 5-level (EQ-5D-5L) (The EQ-5D-5L scores range from 0 to 1. The higher the score, the better.)

    Time frame: Post-treatment and 1, 3, and 6 months after treatment

  8. Valued living (progress, obstruction)

    The each subscale score of Valuing Questionnaire (VQ) (The scores for both VQ-progress and VQ-obstruction range from 0 to 30. The higher the VQ-progress score, the better; the higher the VQ-obstruction score, the worse.)

    Time frame: Post-treatment and 1, 3, and 6 months after treatment

  9. Cognitive fusion

    The total score of Cognitive Fusion Questionnaire (CFQ) (The CFQ scores range from 7 to 49 points. The higher the score, the worse.)

    Time frame: Post-treatment and 1, 3, and 6 months after treatment

  10. Somatic symptom burden

    The total score of Somatic Symptom Scale-8 (SSS-8) (The SSS-8 scores range from 0 to 32. The higher the score, the worse.)

    Time frame: Post-treatment and 1, 3, and 6 months after treatment

07

Study locations

1 site
  • Nagoya City University
    Nagoya, Aichi 467-8601, Japan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Oct 2021, 54 months.

Of 84 non-industry interventional studies with no phase under Dizziness, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's 54 months is above that.

Counting every sponsor, half of 92 studies reached it within 19 months; a quarter within 8 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2017
First posted
Jan 24, 2017
StartActual
Apr 25, 2017
Primary completionActual
Oct 31, 2021
CompletionActual
Oct 31, 2021
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03029949
Lead sponsor
Nagoya City University
Responsible party
Masaki Kondo (MD, PhD, Nagoya City University) — Principal investigator
First posted
Jan 24, 2017
Start date
Apr 25, 2017
Primary completion
Oct 31, 2021
Completion
Oct 31, 2021
Last update
Nov 15, 2023

Study contacts

Masaki Kondo, MD, PhD
principal investigator · Nagoya City University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion